140 related articles for article (PubMed ID: 34887132)
21. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
22. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
[TBL] [Abstract][Full Text] [Related]
23. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.
Okamoto S; Matsuoka S; Takenaka N; Haredy AM; Tanimoto T; Gomi Y; Ishikawa T; Akagi T; Akashi M; Okuno Y; Mori Y; Yamanishi K
Clin Vaccine Immunol; 2012 Jul; 19(7):979-90. PubMed ID: 22552600
[TBL] [Abstract][Full Text] [Related]
24. CCR2 Regulates Vaccine-Induced Mucosal T-Cell Memory to Influenza A Virus.
Lee W; Kingstad-Bakke B; Kedl RM; Kawaoka Y; Suresh M
J Virol; 2021 Jul; 95(15):e0053021. PubMed ID: 33952647
[TBL] [Abstract][Full Text] [Related]
25. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
26. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
[TBL] [Abstract][Full Text] [Related]
27. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
[TBL] [Abstract][Full Text] [Related]
28. Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.
Falkeborn T; Bråve A; Larsson M; Akerlind B; Schröder U; Hinkula J
PLoS One; 2013; 8(8):e70527. PubMed ID: 23950951
[TBL] [Abstract][Full Text] [Related]
29. H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.
Qin T; Yin Y; Huang L; Yu Q; Yang Q
Clin Vaccine Immunol; 2015 Apr; 22(4):421-9. PubMed ID: 25673304
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens.
Shim DH; Ko HJ; Volker G; Potter AA; Mutwiri G; Babiuk LA; Kweon MN
Vaccine; 2010 Mar; 28(11):2311-7. PubMed ID: 20060944
[TBL] [Abstract][Full Text] [Related]
31. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
[TBL] [Abstract][Full Text] [Related]
32. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
[TBL] [Abstract][Full Text] [Related]
33. N-dihydrogalactochitosan serves as an effective mucosal adjuvant for intranasal vaccine in combination with recombinant viral proteins against respiratory infection.
Hoover AR; More S; Liu K; West CL; Valerio TI; Furrer CL; Adams JP; Yu N; Villalva C; Kumar A; Alleruzzo L; Lam SSK; Hode T; Papin JF; Chen WR
Acta Biomater; 2024 Feb; 175():279-292. PubMed ID: 38160856
[TBL] [Abstract][Full Text] [Related]
34. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.
Bracci L; Canini I; Puzelli S; Sestili P; Venditti M; Spada M; Donatelli I; Belardelli F; Proietti E
Vaccine; 2005 Apr; 23(23):2994-3004. PubMed ID: 15811645
[TBL] [Abstract][Full Text] [Related]
35. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ
Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171
[TBL] [Abstract][Full Text] [Related]
36. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
[TBL] [Abstract][Full Text] [Related]
37. Oil-in-ionic liquid nanoemulsion-based intranasal delivery system for influenza split-virus vaccine.
Lin X; Sheng Y; Zhang X; Li Z; Yang Y; Wu J; Su Z; Ma G; Zhang S
J Control Release; 2022 Jun; 346():380-391. PubMed ID: 35483639
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration.
Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z
Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271
[TBL] [Abstract][Full Text] [Related]
39. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
[TBL] [Abstract][Full Text] [Related]
40. The intranasal adjuvant Endocine™ enhances both systemic and mucosal immune responses in aged mice immunized with influenza antigen.
Falkeborn T; Hinkula J; Olliver M; Lindberg A; Maltais AK
Virol J; 2017 Mar; 14(1):44. PubMed ID: 28253901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
